BidaskClub upgraded shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from a sell rating to a hold rating in a research note issued to investors on Thursday, BidAskClub reports.

ALXN has been the subject of several other reports. Wedbush assumed coverage on Alexion Pharmaceuticals in a report on Wednesday, May 22nd. They issued an outperform rating and a $173.00 target price for the company. Citigroup dropped their target price on Alexion Pharmaceuticals from $180.00 to $165.00 and set a buy rating for the company in a report on Thursday, May 23rd. Royal Bank of Canada restated an outperform rating and issued a $186.00 target price (up from $165.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, March 27th. Guggenheim assumed coverage on Alexion Pharmaceuticals in a report on Friday, February 22nd. They issued a neutral rating and a $135.00 target price for the company. Finally, Raymond James assumed coverage on Alexion Pharmaceuticals in a report on Wednesday, April 10th. They issued an outperform rating and a $161.00 target price for the company. Seven equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The company currently has an average rating of Buy and an average price target of $161.06.

Shares of NASDAQ:ALXN opened at $117.93 on Thursday. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.87 and a quick ratio of 3.36. The firm has a market capitalization of $26.44 billion, a price-to-earnings ratio of 14.97, a P/E/G ratio of 0.88 and a beta of 1.58. Alexion Pharmaceuticals has a 52-week low of $92.56 and a 52-week high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.99 by $0.40. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Alexion Pharmaceuticals had a return on equity of 19.53% and a net margin of 9.59%. The firm’s quarterly revenue was up 22.5% on a year-over-year basis. During the same period in the prior year, the business earned $1.68 EPS. As a group, equities analysts expect that Alexion Pharmaceuticals will post 8.61 earnings per share for the current fiscal year.

In other news, Director Bros. Advisors Lp Baker sold 123,489 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $126.53, for a total value of $15,625,063.17. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 4.08% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Investors Research Corp acquired a new position in Alexion Pharmaceuticals during the 1st quarter worth about $27,000. Thor Advisors LLC acquired a new position in Alexion Pharmaceuticals during the 1st quarter worth about $34,000. Institutional & Family Asset Management LLC lifted its stake in Alexion Pharmaceuticals by 39.5% during the 1st quarter. Institutional & Family Asset Management LLC now owns 307 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 87 shares in the last quarter. Captrust Financial Advisors acquired a new position in Alexion Pharmaceuticals during the 4th quarter worth about $31,000. Finally, Berman Capital Advisors LLC lifted its stake in Alexion Pharmaceuticals by 68.6% during the 1st quarter. Berman Capital Advisors LLC now owns 322 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 131 shares in the last quarter. 94.51% of the stock is currently owned by institutional investors and hedge funds.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Read More: Back-End Load

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.